Traversal raises $120M at a $1B valuation to fix what AI code breaks
THE SO WHAT
A $120M Series B for Traversal’s AI SRE agents is a direct bet that debugging and reliability—not generation—are the real choke points in AI-augmented software. If you’re scaling AI-written code, budget now for observability, test, and auto-remediation tooling or you’ll pay it back in outages.
READ THE SOURCE
MORE FROM THE WIRE
Startups & Venturebit.bio raises $25M Series D as demand for its human cell models grows
Demand for programmable human cell models is a bet that in vitro biology will keep pulling work away from animal models and slow, bespoke wet labs. If you’re in drug discovery or tools, assume partners will expect tighter integration with standardized cell platforms over the next 12–24 months.
Startups & VentureEIC Scaling Club deep tech scale-ups raised €4bn after joining, report says
€4.06B raised across 120 EIC Scaling Club companies shows Europe is quietly building a deep tech capital lane that doesn’t rely on U.S. markets. If you’re a European hard-tech operator, this is a signal to map Brussels and EIC programs into your fundraising strategy, not just Sand Hill and sovereign funds.
Startups & VentureStation F names its 40 best-performing startups of 2026
Curated “top 40” lists from hubs like Station F are soft power tools — they shape which teams get the next wave of capital, talent, and distribution intros. If you’re building in Europe, treat inclusion on these lists as a go-to-market accelerant worth planning for, and absence as a signal to double down on direct customer proof instead.
Startups & VentureEncube Ethicals Said to Plan $317 Million India IPO This Month
A $317M Mumbai IPO for Encube Ethicals is another data point that Indian public markets will finance scaled, specialized pharma rather than waiting for Western exits. Founders in India’s health and life sciences stack can underwrite more of their growth plans to domestic equity markets, not just global PE.